Norstella
Norstella is a global pharmaceutical technology company dedicated to smoothing the path to life-saving therapies through a range of consultancy services and solutions, with brands including Citeline, Evaluate, MMIT, Panalgo, and The Dedham Group.
About Norstella
Norstella's mission is to smooth the path to life-saving therapies for patients and providers. Norstella comprises prominent pharmaceutical solution providers, united to offer a full range of consultancy services and solutions. The company aids clients in navigating the complexities of the drug development life cycle. Norstella's brands include Citeline, Evaluate, MMIT, Panalgo, and The Dedham Group, all playing key roles in providing targeted solutions and insights to the pharmaceutical industry.
Norstella's Key Brands
Norstella's portfolio features several specialized brands. Citeline accelerates the connection of treatments to patients and vice versa. Evaluate offers data, insight, and intelligence to facilitate confident decision-making in treatment investments. MMIT provides market access data, analytics, and insights. Panalgo enhances healthcare data analytics through intuitive software solutions. The Dedham Group specializes in U.S. market access strategic consulting for oncology and specialty therapeutics life sciences organizations.
Norstella's Global Presence
Norstella maintains a robust global presence with offices in London, Boston, Japan, Yardley, Livingston, Washington DC, The Netherlands, and New York. This international footprint enables the company to deliver its services and solutions to a diverse, worldwide clientele, ensuring that life-saving therapies reach patients globally.
Norstella's Notable Initiatives and Predictions
Norstella has launched several notable initiatives and made significant market predictions. Citeline, in particular, has been influential in clinical development success rate analyses and launched TrialScope Intelligence for clinical trial disclosure complexity. Evaluate acquired J+D Forecasting to enhance its forecasting solutions. Norstella predicts the ADC market, primarily driven by oncology, will grow to $28 billion per year by 2028.
Norstella's Analytics and Reports
Norstella provides comprehensive analytics and strategic reports to support the pharmaceutical industry. Their Patient Access Analytics combines coverage and claims data to offer insights on payer and prescriber behavior. The Strategic Launch Report offers drug manufacturers a view of payers’ coverage adoption rates post-launch. PULSE Analytics targets integrated delivery networks (IDNs) with granular data sets. These tools empower commercial pharma teams to make informed decisions.